Lessons from immuno-oncology: a new era for cancer nanomedicine?

Nature Reviews Drug Discovery 16, 369 (2017). doi:10.1038/nrd.2017.34 Authors: Wen Jiang, Hengfeng Yuan, Charles K. Chan, Christina A. von Roemeling, Zuoqin Yan, Irving L. Weissman & Betty Y. S. Kim Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons learned from the successes with immuno-oncology therapies could be applied to cancer nanomedicine and how this may help to overcome some
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: Comment Source Type: research